Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : X-Pact
Therapeutic Area : Oncology
Study Phase : Undisclosed
Recipient : Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins
Deal Size : Inapplicable
Deal Type : Inapplicable
Single Patient Compassionate Use of X-PACT in Salvage Treatment of Prostate Cancer
Details : Undisclosed
Product Name : Undisclosed
Product Type : HPAPI
Upfront Cash : Inapplicable
February 20, 2025
Lead Product(s) : X-Pact
Therapeutic Area : Oncology
Highest Development Status : Undisclosed
Recipient : Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Methoxsalen
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Recruiting Patients for Phase 1 Trial of the X-PACT System in Solid Tumors
Details : The heart of the X-PACT system is 8-MOP (also known as 8-methoxypsoralen or methoxsalen) which has been successfully used for decades in the treatment of autoimmune disease, skin disorders and certain skin and blood cancers.
Product Name : X-PACT System
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 16, 2021
Lead Product(s) : Methoxsalen
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
X-ray Psoralen Activated Cancer Therapy in Head and Neck, Breast, Sarcoma and Melanoma
Details : Undisclosed
Product Name : Undisclosed
Product Type : HPAPI
Upfront Cash : Inapplicable
May 15, 2020